Press Releases

Hangzhou, CHINA, March 19, 2021 – WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has entered into a long-term strategic collaboration with Worg Pharma (“Worg”), a clinical stage biopharmaceutical company in Hangzhou, China.

Leveraging its well-established Microbial and Viral Platforms (MVP), WuXi Biologics will provide technical support and services for the process development, manufacturing and global IND for multiple biologics, further enabling Worg to advance the new-generation Allergen-Specific Immunotherapy (ASIT).

“As a clinical stage biopharmaceutical company, we have been devoted to developing new treatments for allergy and other diseases with high unmet medical needs and considerable commercial potential,” said Dr. Aiwu Xu, Chairman and CEO of Worg. “We are honored that WuXi Biologics’ leadership in biologics development and manufacturing can help us expedite developing robust platforms of allergy treatments and tackling the unmet clinical needs in the field of allergy immunotherapy. This partnership will allow us to offer more effective and precise solutions for allergy patients around the world.”

“We’re glad to enable Worg with our premier Microbial and Viral Platforms (MVP) to accelerate innovative treatments for allergy patients,” said Dr. Chris Chen, CEO of WuXi Biologics. “With these globally leading platforms in Hangzhou, WuXi Biologics will continue to enable our partners to develop and manufacture next-generation biologics, including recombinant proteins, enzymes, viroid proteins, mRNA vaccines, viral vectors. Currently, there are 8 novel projects enabled by our extraordinary platforms in terms of development, manufacturing and global IND. Looking forward, we will continue to accelerate and transform biologics discovery, development and manufacturing to benefit patients worldwide.”

About Worg Pharma

Worg Pharma (“Worg”) is a clinical stage biopharmaceutical company developing new treatments for allergy and other diseases with high unmet medical needs and considerable commercial potential. Headquartered in Hangzhou at the heart of one of China's biotech hubs, Worg was founded in 2018 and led by an executive team from China, the United States and Europe who have extensive experience in life science executive, pharmaceutical development, clinical trials, regulatory affairs and commercialization. Worg owns the world-wide rights of PCFiT platform, and established pipeline for a number of inhalant allergens. Worg plans to build the pipeline of allergy and other therapeutical indications through internal development and external partnering with flexible options, accelerate the product development, world-wide registration and commercialization.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly one-stop service offering and strong value proposition to its global clients. As of June 30, 2020, there were a total of 286 integrated projects, including 141 projects in pre-clinical development stage, 125 projects in early-phase (phase I and II) clinical development, 19 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany, and Singapore exceeding 300,000 liters after 2023, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

Media
PR@wuxibiologics.com

Investor
IR@wuxibiologics.com